EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL






Immunology Letters 149(1-2): 30-40

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

Recombinant immunotoxins consisting of small antibody fragments fused to cytotoxic moieties are being evaluated for use in prospective antibody-targeted cancer therapies. A receptor tyrosine kinase known as c-Met is overexpressed in a vast range of human malignancies, making it an ideal target for antibody-mediated delivery of numerous cytotoxic agents. A single Fab molecule capable of binding to human c-Met with high affinity and specificity was previously identified using antibody phage-display technology. In order to develop a molecule to increase both the cytotoxicity and anti-tumor activity of the anti-c-Met molecule, a recombinant immunotoxin anti-c-Met/PE38KDEL was constructed and expressed by fusing the human anti-c-Met single-chain variable fragment (ScFv) with a modified Pseudomonas exotoxin A (PE38KDEL). Purified anti-c-Met/PE38KDEL was demonstrated to specifically bind to cells of c-Met-positive human hepatoma cell lines, causing a proliferation defect by inducing caspase-3/8-mediated apoptosis, as observed by in vitro assays. Furthermore, anti-c-Met/PE38KDEL administration was shown to inhibit the growth of hepatocellular carcinoma xenografts in vivo through suppression of Ki-67 expression and enhancement of tumor cell apoptosis rates. Cumulatively, the current findings demonstrate the successful construction of a recombinant immunotoxin capable of accurately targeting c-Met-positive human hepatoma cell lines both in vitro and in vivo, providing a novel compound with potential for applications as an alternative therapy for c-Met-positive cancer management. A recombinant immunotoxin, anti-c-Met/PE38KDEL, was constructed. This immunotoxin can inhibit the proliferation of human hepatoma cell line. This immunotoxin can inhibit the growth of hepatocellular carcinoma xenograft.

(PDF same-day service: $19.90)

Accession: 036599480

PMID: 23026237

DOI: 10.1016/j.imlet.2012.09.006



Related references

Single chain immunotoxin anti-TAC -PE38KDEL that is targeted to kill IL-2R bearing cells. Journal of Molecular Recognition 6(1): 12, 1993

Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. Journal of Biological Chemistry 272(39): 24165-9, 1997

Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Protein Expression and Purification 58(1): 140-147, 2007

Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin. Bioconjugate Chemistry 8(5): 695-701, 1997

Construction and expression of anti-GD2/anti-CD16 single-chain bispecific antibody. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24(3): 659-663, 2007

Construction and expression of anti-CD3/anti-prostate-cancer bispecific single-chain antibody. Zhonghua Yi Xue Za Zhi 83(15): 1292-1295, 2003

Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast. International Journal of Oncology 32(6): 1245-1251, 2008

Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Cancer Research 53(9): 2123-2127, 1993

Construction and characterization of a single chain human beta-glucuronidase-anti-CD20 antibody fusion protein for antibody-directed enzyme prodrug therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 472, 1996

Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. Blood 92(1): 184-190, 1998